Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Amphastar Pharmaceuticals (NDAQ:AMPH) Downgraded at Raymond James to “Outperform” from “Strong Buy” Rating

Raymond James Amphastar Pharmaceuticals NDAQ:AMPH

Amphastar Pharmaceuticals (NDAQ:AMPH) Change of Rating

In an analyst report sent to investors on Tuesday, 14 March, Raymond James has downgraded Amphastar Pharmaceuticals (NDAQ:AMPH) stock to “Outperform”. AMPH’s old rating was “Strong Buy”.

The rating downgrade was noticed by stock traders, as NDAQ:AMPH is currently trading -17.23% lower at $12.20 as of 7:59 AM New York time. Amphastar Pharmaceuticals shares have [From2] 0% over the past 200 days, while the Standard & Poor’s 500 index has surged 13.53% over the same time period.

According to data compiled by Thomson Reuters, Amphastar Pharmaceuticals (NDAQ:AMPH)’s stock is covered by 5 equity analysts across the Street, with 0 analysts giving it a Sell rating, 0 a Buy rating, while 0 consider it a Hold. The 12-month consensus target price for the stock is $17.8, which reflects an upside potential of 45.90% over the current price.

AMPH Stock Chart

Institutional Ownership

Bogle Investment Management L P De had the most significant stake with ownership of 365,603 shares as of Q2 2015 for 0.5% of the stock exposure. Eam Investors Llc is another quite bullish institutional investor who is owning 193,355 shares of Amphastar Pharmaceuticals or 0.49% of their stock exposure. Further, Essex Investment Management Co Llc have 0.37% of their stock exposure invested in the company for 121,666 shares. The Delaware-based fund Kalmar Investments Inc De disclosed it had bought so far a stake worth about 0.22% of the institutional investor’s stock portfolio in Amphastar Pharmaceuticals. The California-based fund Menta Capital Llc is also positive about the stock, possessing 254,418 shares or 0.17% of their stock exposure.

Amphastar Pharmaceuticals (NDAQ:AMPH) Profile

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Amphastar Pharmaceuticals (NDAQ:AMPH) traded down -17.23% on 14 March, hitting $12.2. A total of 1.64 million shares of the company’s stock traded hands. This is up from average of 353,097 shares. Amphastar Pharmaceuticals has a 52 week low of $10.92 and a 52 week high of $21.75. The company has a market cap of $566.10 million and a P/E ratio of 27.03.

Get the latest Amphastar Pharmaceuticals (NDAQ:AMPH) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Amphastar Pharmaceuticals (NDAQ:AMPH) Downgraded at Raymond James to “Outperform” from “Strong Buy” Rating appeared first on Octafinance.

This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Amphastar Pharmaceuticals (NDAQ:AMPH) Downgraded at Raymond James to “Outperform” from “Strong Buy” Rating


Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription